Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease

Movement Disorders

Volumn 31, Issue 10, 2016, Pages 1543-1550

  Fraser, Kyle B ^a   Rawlins, Ashlee B ^a   Clark, Rachel G ^a   Alcalay, Roy N ^b   Standaert, David G ^a   Liu, Nianjun ^c   West, Andrew B ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Columbia University ^*  (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

biomarker; cognitive decline; microvesicles; PARK8

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LEVODOPA;

ADULT; AGED; ARTICLE; AUTOPHOSPHORYLATION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DISEASE DURATION; DISEASE SEVERITY; EPWORTH SLEEPINESS SCALE; EXOSOME; FAMILY HISTORY; FEMALE; GENETIC ASSOCIATION; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MONTREAL COGNITIVE ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; UNIFIED PARKINSON DISEASE RATING SCALE; URINE SAMPLING;

EID: 84991272394     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26686     Document Type: Article

References (33)

1. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005;365(9457):415-416.
2. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44(4):595-600.
3. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44(4):601-607.
4. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7(7):583-590.
5. Alcalay RN, Mirelman A, Saunders-Pullman R, et al. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord 2013;28(14):1966-1971.
6. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014;46(9):989-993.
7. Webber PJ, Smith AD, Sen S, Renfrow MB, Mobley JA, West AB. Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J Mol Biol 2011;412(1):94-110.
8. Sheng Z, Zhang S, Bustos D, et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med 2012;4(164):164ra161.
9. West AB, Moore DJ, Choi C, et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Gen 2007;16(2):223-232.
10. West AB, Moore DJ, Biskup S, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 2005;102(46):16842-16847.
11. Fraser KB, Moehle MS, Alcalay RN, West AB. LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers. Neurology 2016;86(11):994-999.
12. Henderson JL, Kormos BL, Hayward MM, et al. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem 2015;58(1):419-432.
13. Fraser KB, Moehle MS, Daher JP, et al. LRRK2 secretion in exosomes is regulated by 14-3-3. Hum Mol Gen 2013;22(24):4988-5000.
14. Rocca WA, Maraganore DM, McDonnell SK, Schaid DJ. Validation of a telephone questionnaire for Parkinson's disease. J Clin Epidemiol 1998;51(6):517-523.
15. Nalls MA, Bras J, Hernandez DG, et al. NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol Aging 2015;36(3):1605.e7–1605.12.
16. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25(15):2649-2653.
17. Rosenthal LS, Drake D, Alcalay RN, et al. The NINDS Parkinson's disease biomarkers program. Mov Disord 2015. doi: 10.1002/mds.26438
18. Bailar JC 3rd, Mosteller F. Guidelines for statistical reporting in articles for medical journals. Amplifications and explanations. Ann Intern Med 1988;108(2):266-273.
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57(1):289-300.
20. Moehle MS, Webber PJ, Tse T, et al. LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 2012;32(5):1602-1611.
21. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995;202(1-2):17-20.
22. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994;165(1-2):208-210.
23. Muller T, Blum-Degen D, Przuntek H, Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand 1998;98(2):142-144.
24. Umemura A, Oeda T, Yamamoto K, et al. Baseline plasma C-reactive protein concentrations and motor prognosis in Parkinson disease. PloS ONE 2015;10(8):e0136722.
25. Chen-Plotkin AS. Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron 2014;84(3):594-607.
26. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5(3):228-234.
27. Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013;70(10):1277-1287.
28. Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006;349(1):162-166.
29. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133(Pt 3):713-726.
30. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10(3):230-240.
31. Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010;75(20):1766-1772.
32. Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J Clin Neurol 2011;7(4):215-222.
33. Lin CH, Wu RM. Biomarkers of cognitive decline in Parkinson's disease. Parkinsonism Relat Disord 2015;21(5):431-443.